Myrobalan Therapeutics

🎉 We are thrilled to announce that Dr. Ed Wu joined the Myrobalan team as Vice President, Head of Medicinal Chemistry today. With over 20 years of industry experience, Ed is a seasoned medicinal chemist with a proven track record of successfully advancing multiple compound drugs through the clinic. He joins us from Tango Therapeutics, where he served as the Senior Director of Chemistry. Prior to that, Ed held roles at Mitobridge (an Astellas company), Hydra Biosciences, and Alantos Pharmaceuticals (later acquired by Amgen). Ed holds a BS in Chemistry from Peking University in Beijing and a PhD in Organic Chemistry from SUNY Stony Brook. #WelcomeEd #MedicinalChemistry #MyrobalanTherapeutics #TeamMyro #Pharmaceuticals #Chemistry #IndustryLeaders

Myrobalan Therapeutics is thrilled to welcome Robin Kleiman, Ph.D., as our Chief Scientific Officer!   With 25+ years of neuroscience drug discovery experience across biotech, pharma, and academia, Robin is joining us at an incredible time. She has driven the discovery and development of multiple clinical candidates, leveraging her expertise to translate biology into innovative CNS therapies. Robin has previously led CNS biology at Alkermes, where she strengthened preclinical support for a range of CNS indications. She also founded the Translational Cellular Sciences group at Biogen and contributed to the development of Boston Children’s Hospital Translational Neuroscience Center. Through her career, she has advanced multiple clinical candidates for novel CNS targets. We’re confident that Robin will advance our programs in neuroinflammation and remyelination and ultimately develop transformative treatments for CNS disorders. Welcome to the team, Robin! https://lnkd.in/e7w8YeK4 https://lnkd.in/ekWWqTEF

Myrobalan Therapeutics and other biotech companies have recently been made aware of a growing number of email scams targeting job candidates in our industry. Our recruiters at Myro use @myrotx.com email addresses exclusively. We do not ask candidates to purchase anything through us or to provide sensitive identifiable information via email. You will also never get a text from our recruitment team regarding a job application. If a person claiming to be a Myro recruiter with an alternative domain reaches out to you regarding a job posting, please report it to our team by emailing info@myrotx.com with details. 

This Sunday, the Myrobalan Therapeutics team was honored to participate in the ALS Association's Walk to Defeat ALS in Boston. Walking alongside patients, families, and advocates was a humbling reminder of why we are committed to advancing innovative therapies for neuroinflammatory diseases like ALS. Together, we can make strides toward a future without ALS! 💙 #WalkToDefeatALS #ALSResearch #Neuroinflammation #TeamMyrobalan #BostonEvents #ALS

We'd like to extend a warm welcome to Ms. Emma Reeve, our newest Board Member! With over 30 years of financial leadership in biotech, Emma brings invaluable expertise to Myrobalan as the company plans to grow and advance its programs into the clinic. Previously, Emma served as Chief Financial Officer at Constellation Pharmaceuticals through the successful IPO in 2018 and its ultimate acquisition by MorphoSys AG in 2021. Before her time at Constellation, Ms. Reeve was the interim Chief Financial Officer and Corporate Controller at Parexel. Emma Reeve currently serves as Chair of the Board at Editas Medicine and is a board member at PTC Therapeutics, Aadi Bioscience, Cardurion Pharma, and ReAlta Life Sciences. We look forward to paving the path forward together with Emma! https://lnkd.in/ecZrUaxn https://lnkd.in/e-ywMGjm

Myrobalan is proud to be a local sponsor of the Walk to Defeat ALS in Boston on Oct 20th. This signature event is focused on supporting and advocating for patients and families living with ALS, a prominent and debilitating neurodegenerative disease with no cure. Myrobalan is deeply committed to discovering first and best-in-class small molecule treatments for neurodegenerative diseases such as ALS. Help us make strides toward treatments and cures by donating to the ALS Association. 

We are excited to present our poster on our oral, CNS-penetrant CSF1R inhibitor at the Society for Neuroscience 2024 in Chicago! We look forward to making strides toward therapies for patients suffering from neuroinflammatory diseases.   🧠 Title: Targeting Chronically Active Microglia: CSF1R Inhibition for Treating Multiple Sclerosis 🗓 Date: Sunday, October 6, 2024 ⏰ Time: 1:00- 5:00 p.m. Central Time 📍 Session: Multiple Sclerosis, Leukodystrophies, and Oligodendrocyte Myelination Poster#: PSTR105.18   #SfN24 #Neuroscience #Innovation #Neuroinflammation

We are thrilled to announce the creation of a new role at Myrobalan: Interim Chief Medical Officer (CMO). This position reflects our growing commitment to advancing our pipeline and bringing life-changing therapies to patients in need. With our lead program moving into the clinic next year, having strong medical and clinical leadership is more crucial than ever. We’re looking forward to welcoming a passionate and experienced leader who will help guide us through this pivotal phase and beyond. Stay tuned for more updates as we continue to expand our team and capabilities! #Hiring

ICYMI, we are presenting data on our GPR17 program at ECTRIMS today! https://lnkd.in/ev4djYms

We are pleased to announce our upcoming poster presentation at ECTRIMS 2024 in Copenhagen! Our team will be showcasing a poster on our GPR17 antagonist program, a novel remyelination target. 🗓 Date: Wednesday, 18 September 2024 ⏰ Time: 16:15 – 18:15 CEST 📍 Location: Poster Session 1, Poster # P171 Join us to learn more about our research aimed at developing innovative therapies for demyelinating diseases. #ECTRIMS2024 #Remyelination #DemyelinatingDiseases #Neuroscience #GPR17 #Innovation